Session: SAT 532-553-Hyperandrogenic Disorders
Poster Board SAT-541
Objective: To assess if six months treatment with GLP-1 analogue, liraglutide, improves markers of liver fibrosis.
Design: A case-control study comparing women with PCOS to age and weight matched controls. PCOS was diagnosed according to the Rotterdam criteria. All participants underwent liver function tests and liver ultrasound scan to assess for fatty infiltration. Serum markers for liver fibrosis, PIIINP and HA, were measured at baseline and after six months of treatment with Liraglutide 1.8mg od. Data were summarised by the mean and standard deviation and analysed using the independent or dependent t-test.
Results: Twenty one obese women with PCOS and 19 controls were recruited, age (32.8±7.2 vs. 33.5±6.7years) and weight (100.9±16.7 vs. 99.3±14.7kg), respectively.
At baseline, the PCOS group had higher testosterone 1.2±0.3 vs. 0.9±0.3nmol/L (P=0.01), HOMA-IR 2.5±1.7 vs. 1.7±1.0 (P=0.08), urinary isoprostane 16.0±4.4 vs. 11.8±7.1ng/ml (P=0.04), fatty infiltration suggestive of NAFLD seven (35%) vs. none, aspartate aminotransferase (AST) 22.4 ±5.2 vs.18.8 ±3.4u/L (P=0.04), and PIIINP 4.4 ±0.8 vs. 3.5±0.8 ug/ml (P=0.01), compared to controls. NAFLD clinical score (BARD), alanine aminotransferase and HA did not significantly differ between the two groups.
Twenty five (62%) participants completed the study (13 PCOS, 12 controls). Following treatment, weight was reduced by 3.7±4.8kg (P=0.016) and 4.6±3.5kg (P=0.001); triglycerides by 0.4±0.5mmol/L (P=0.007) and 0.3±0.5mmol/L (P=0.057); and PIIINP by 0.8±0.8ug/ml (P=0.005) and 0.6±0.8 ug/ml (P=0.02) in the PCOS and control groups, respectively.
Conclusions: Treatment with the GLP-1 analogue, liraglutide, and/or associated weight loss significantly reduced the levels of liver fibrosis marker PIIINP in obese women with PCOS and controls. Liraglutide may be a potential treatment for women with PCOS, obesity and NAFLD.
Nothing to Disclose: HK, GA, ASR, AMC, ESK, SLA
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters